<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778906</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-477</org_study_id>
    <nct_id>NCT02778906</nct_id>
  </id_info>
  <brief_title>Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia</brief_title>
  <acronym>ARIAA</acronym>
  <official_title>Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia (ARIAA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with
      ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at
      baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6
      months vs. Group 2: Placebo s.c. for 6 months. After 6 months both groups will run into the
      follow up period for another 12 months up to month 18. Patients developing arthritis will be
      treated according to local guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with an improvement of acute inflammation characterised as improvement of synovitis (synovialitis or tenosynovitis) or osteitis in the MRI of the dominant hand after 6 months of treatment with abatacept or placebo</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RAMRIS synovitis score in the dominant hand 12 and 18 months.</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tenosynovitis score in the dominant hand.</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with new or persistent arthralgia.</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disappearance of arthralgia.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical arthritis defined by joint swelling</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with RA (ACR/EULAR 2010 criteria)</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with radiological progress in HR-pQCT analysis comparing baseline image with end of study image.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count 68</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity score (DAS) 28</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) pain</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of joint stiffness</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>6,12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheumatoid Arthritis Impact of Disease (RAID)</measure>
    <time_frame>6,12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36)</measure>
    <time_frame>6,12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density (BMD)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone volume per tissue volume (BV/TV)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical width in the micro-CT of the distal radius</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical porosity in the micro-CT of the distal radius</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAMRIS erosion score in the dominant hand 12 and 18 months.</measure>
    <time_frame>6. 12. 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAMRIS osteitis score in the dominant hand 12 and 18 months.</measure>
    <time_frame>6,12,18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count 68</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) patient global</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS) physician global</measure>
    <time_frame>3,6,9,12,15 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical width in the micro-CT of the metacarpal heads</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical porosity in the micro-CT of the metacarpal heads</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Arthralgia</condition>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abatacept 125 mg s.c. weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (NaCl 0,9%) s.c. weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of the comparator s.c. weekly in comparable to verum</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males aged ≥ 18 years at time of consent

          -  ACPA (with or without RF)

          -  Joint pain (hand, feet, knee, shoulder or elbow) present for at least 6 weeks prior to
             inclusion or in past history

          -  Presence of synovitis (synovialitis or tenosynovitis) or osteitis in MRI of the
             dominant hand at baseline

          -  Women of childbearing potential or men capable of fathering children must be using
             effective contraception during treatment with abatacept and up to 14 weeks after the
             last dose of abatacept treatment.

          -  Must understand and voluntarily sign an informed consent form including written
             consent for data protection

          -  Must be able to adhere to the study visit schedule and other protocol requirements

        Exclusion Criteria:

          -  Presence of arthritis in hand, feet, knee, shoulder or elbow joints defined as
             swelling

          -  Current treatment with glucocorticoids conventional or biologic DMARDs

          -  Previous treatment with abatacept

          -  Investigational study drug within 4 weeks (or 5 half lives, whichever is longer) prior
             to randomization

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, SpA, Behcet
             disease, vasculitis or autoimmune hepatitis.

          -  Any malignancy in the last 5 years

          -  Chronic infection such as latent TB (TB not adequately treated according to
             guidelines) or hepatitis B or C infection

          -  Immunocompromised or HIV-positive patients

          -  Uncontrolled severe concomitant disease

          -  Patients who are younger than 18 years or are incapable to understand the aim,
             importance and consequences of the study and to give legal informed consent (according
             to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG).

          -  Pregnant or lactating females

          -  Patients who possibly are dependent on the Principal Investigator or Investigator
             (e.g. family members).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Schett, Prof. Dr. univ.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Erlangen, Department of Internal Medicine 3, Rheumatology &amp; Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen Rech, Dr.med.</last_name>
    <phone>+49-91318543014</phone>
    <email>juergen.rech@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg Schett, Prof. Dr. univ.</last_name>
    <phone>+49-91318539133</phone>
    <email>georg.schett@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Bad Abbach</name>
      <address>
        <city>Bad Abbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Fleck, Prof. Dr. med.</last_name>
      <email>m.fleck@asklepios.com</email>
    </contact>
    <contact_backup>
      <last_name>Boris Ehrenstein, Dr. med.</last_name>
      <email>boris.ehrenstein@klinik.uni-r.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramona Koenig, Dr. med.</last_name>
      <email>r.koenig@kerckhoff-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulf Müller-Ladner, Prof. Dr. med.</last_name>
      <email>u.mueller-ladner@kerckhoff-klinik.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugen Feist, Prof. Dr. med.</last_name>
      <email>eugen.feist@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Kedor, Dr. med.</last_name>
      <email>claudia.kedor@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Praxis für Rheumatologie und Innere Medizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Karberg, Dr. med.</last_name>
      <email>kirsten.karberg@arcor.de</email>
    </contact>
    <contact_backup>
      <last_name>Henning Brandt, Dr. med.</last_name>
      <email>henning.brandt@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schlosspark Klinik</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rieke Alten, Dr. med.</last_name>
      <email>Rieke.Alten@schlosspark-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Pohl, Dr. med.</last_name>
      <email>christof.pohl@schlosspark-klinik.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinic Burghausen</name>
      <address>
        <city>Burghausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Feuchtenberger, Dr. med.</last_name>
      <phone>+49 (0) 86 77 / 880-261</phone>
      <email>m.feuchtenberger@krk-bgh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Hueber, Dr. med. Dr. PhD</last_name>
      <phone>+49-913185320193</phone>
      <email>axel.hueber@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Juergen Rech, Dr. med.</last_name>
      <phone>+49-91318543014</phone>
      <email>juergen.rech@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrum für innovative Diagnostik und Therapie (Ciri) Rheumatologie/Immunologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Behrens, Dr. med.</last_name>
      <phone>069/6301-7302</phone>
      <email>Behrens@ciri-clinical.de</email>
    </contact>
    <contact_backup>
      <last_name>Harald Burkhardt, Prof. Dr. med.</last_name>
      <phone>069/6301-7301</phone>
      <email>burkhardt@ciri-clinical.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Voll, Prof. Dr. med.</last_name>
      <email>reinhard.voll@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens Thiel, Dr. med.</last_name>
      <email>jens.thiel@uniklinik-freiburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nils Venhoff, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xenofon Baraliakos, Dr. med.</last_name>
      <email>baraliakos@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Uta Kiltz, Dr. med.</last_name>
      <email>Uta.Kiltz@elisabethgruppe.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Porz Am Rhein</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Strunk, Prof. Dr. med.</last_name>
      <email>j.strunk@khporz.de</email>
    </contact>
    <contact_backup>
      <last_name>Dennis Schleicht, Dr. med.</last_name>
      <email>D.Scheicht@khporz.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abatacept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

